People in intensive care with COVID-19: demographic and clinical features during the first, second, and third pandemic waves in Australia.


Journal

The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714

Informations de publication

Date de publication:
03 10 2022
Historique:
revised: 21 03 2022
received: 10 01 2022
accepted: 24 03 2022
pubmed: 11 6 2022
medline: 28 9 2022
entrez: 10 6 2022
Statut: ppublish

Résumé

To compare the demographic and clinical features, management, and outcomes for patients admitted with COVID-19 to intensive care units (ICUs) during the first, second, and third waves of the pandemic in Australia. People aged 16 years or more admitted with polymerase chain reaction-confirmed COVID-19 to the 78 Australian ICUs participating in the Short Period Incidence Study of Severe Acute Respiratory Infection (SPRINT-SARI) Australia project during the first (27 February - 30 June 2020), second (1 July 2020 - 25 June 2021), and third COVID-19 waves (26 June - 1 November 2021). Primary outcome: in-hospital mortality. ICU mortality; ICU and hospital lengths of stay; supportive and disease-specific therapies. 2493 people (1535 men, 62%) were admitted to 59 ICUs: 214 during the first (9%), 296 during the second (12%), and 1983 during the third wave (80%). The median age was 64 (IQR, 54-72) years during the first wave, 58 (IQR, 49-68) years during the second, and 54 (IQR, 41-65) years during the third. The proportion without co-existing illnesses was largest during the third wave (41%; first wave, 32%; second wave, 29%). The proportion of ICU beds occupied by patients with COVID-19 was 2.8% (95% CI, 2.7-2.9%) during the first, 4.6% (95% CI, 4.3-5.1%) during the second, and 19.1% (95% CI, 17.9-20.2%) during the third wave. Non-invasive (42% v 15%) and prone ventilation strategies (63% v 15%) were used more frequently during the third wave than during the first two waves. Thirty patients (14%) died in hospital during the first wave, 35 (12%) during the second, and 281 (17%) during the third. After adjusting for age, illness severity, and other covariates, the risk of in-hospital mortality was similar for the first and second waves, but 9.60 (95% CI, 3.52-16.7) percentage points higher during the third than the first wave. The demographic characteristics of patients in intensive care with COVID-19 and the treatments they received during the third pandemic wave differed from those of the first two waves. Adjusted in-hospital mortality was highest during the third wave.

Identifiants

pubmed: 35686307
doi: 10.5694/mja2.51590
pmc: PMC9347520
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-360

Subventions

Organisme : Department of Health, Commonwealth of Australia
ID : Standing Deed SON60002733

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

Références

N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
Clin Infect Dis. 2022 Aug 24;75(1):e1128-e1136
pubmed: 34423834
Nat Commun. 2021 Nov 1;12(1):6266
pubmed: 34725323
Elife. 2020 Aug 13;9:
pubmed: 32788039
PLoS One. 2021 Sep 30;16(9):e0257643
pubmed: 34591896
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
Lancet Reg Health Am. 2021 Nov;3:100041
pubmed: 34423331
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34369565
Ultrasound Obstet Gynecol. 2021 Feb;57(2):224-231
pubmed: 33320401
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Lancet Digit Health. 2021 Sep;3(9):e539-e541
pubmed: 34384736
PLoS One. 2020 Feb 14;15(2):e0228208
pubmed: 32059001
Med J Aust. 2021 Jan;214(1):23-30
pubmed: 33325070
BMC Med. 2021 Aug 30;19(1):213
pubmed: 34461893
Med J Aust. 2021 Apr;214(7):297-298.e1
pubmed: 33774832
Med J Aust. 2021 Dec 13;215(11):513-517
pubmed: 34642941

Auteurs

Husna Begum (H)

Monash University, Melbourne, VIC.

Ary S Neto (AS)

Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC.

Patricia Alliegro (P)

Alfred Health, Melbourne, VIC.

Tessa Broadley (T)

Monash University, Melbourne, VIC.

Tony Trapani (T)

Monash University, Melbourne, VIC.
Alfred Health, Melbourne, VIC.

Lewis T Campbell (LT)

Royal Darwin Hospital, Darwin, NT.
Menzies School of Health Research, Darwin, NT.

Allen C Cheng (AC)

Monash University, Melbourne, VIC.

Winston Cheung (W)

Concord Repatriation General Hospital, Sydney, NSW.

D James Cooper (DJ)

Monash University, Melbourne, VIC.
Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC.
Alfred Health, Melbourne, VIC.

Simon J Erickson (SJ)

Princess Margaret Hospital for Children, Perth, WA.

Craig J French (CJ)

Western Heath, Melbourne, VIC.

Edward Litton (E)

Fiona Stanley Hospital, Perth, WA.

Richard McAllister (R)

Royal Hobart Hospital, Hobart, TAS.

Alistair Nichol (A)

Monash University, Melbourne, VIC.
Alfred Health, Melbourne, VIC.

Annamaria Palermo (A)

Fiona Stanley Hospital, Perth, WA.
St John of God Health Care, Perth, WA.

Mark P Plummer (MP)

Royal Melbourne Hospital, Melbourne, VIC.

Hannah Rotherham (H)

Royal Melbourne Hospital, Melbourne, VIC.

Mahesh Ramanan (M)

Prince Charles Hospital, Brisbane, QLD.
Caboolture Hospital, Caboolture, QLD.

Benjamin Reddi (B)

Royal Adelaide Hospital, Adelaide, SA.

Claire Reynolds (C)

St Vincent's Hospital, Sydney, NSW.

Steven Ar Webb (SA)

University of Western Australia, Perth, WA.

Andrew A Udy (AA)

Monash University, Melbourne, VIC.
Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC.

Aidan Burrell (A)

Alfred Health, Melbourne, VIC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH